$4.86
2.32% yesterday
Nasdaq, Nov 25, 10:04 pm CET
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Relay Therapeutics Inc Stock price

$4.86
-1.16 19.27% 1M
-1.96 28.74% 6M
-6.15 55.86% YTD
-2.97 37.93% 1Y
-26.54 84.52% 3Y
-30.19 86.13% 5Y
-30.19 86.13% 10Y
Nasdaq, Closing price Mon, Nov 25 2024
+0.11 2.32%
ISIN
US75943R1023
Symbol
RLAY
Sector
Industry

Key metrics

Market capitalization $813.48m
Enterprise Value $23.69m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 2.37
P/S ratio (TTM) P/S ratio 81.27
P/B ratio (TTM) P/B ratio 0.97
Revenue growth (TTM) Revenue growth -61.21%
Revenue (TTM) Revenue $10.01m
EBIT (operating result TTM) EBIT $-394.96m
Free Cash Flow (TTM) Free Cash Flow $-282.56m
Cash position $839.61m
EPS (TTM) EPS $-2.61
P/E forward negative
P/S forward 80.72
EV/Sales forward 2.35
Short interest 8.76%
Show more

Is Relay Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.

Relay Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Relay Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Relay Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
10 10
61% 61%
100%
- Direct Costs 5.51 5.51
9% 9%
55%
4.50 4.50
78% 78%
45%
- Selling and Administrative Expenses 65 65
2% 2%
654%
- Research and Development Expense 329 329
3% 3%
3,282%
-389 -389
7% 7%
-3,891%
- Depreciation and Amortization 5.51 5.51
9% 9%
55%
EBIT (Operating Income) EBIT -395 -395
7% 7%
-3,946%
Net Profit -345 -345
6% 6%
-3,449%

In millions USD.

Don't miss a Thing! We will send you all news about Relay Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Relay Therapeutics Inc Stock News

Neutral
GlobeNewsWire
20 days ago
Reported interim RLY-2608 data demonstrating 9.2-month median PFS in heavily pre-treated patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer at RP2D
Neutral
GlobeNewsWire
27 days ago
CAMBRIDGE, Mass., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report third quarter 2024 financial results and corporate highlights after the U.S. financial markets close on Wednesday, November 6, 2024.
Positive
Seeking Alpha
2 months ago
Relay Therapeutics, Inc. reported positive interim data from its phase 1 ReDiscover study, using RLY-2608 + fulvestrant for treatment of PI3Ka-mutated HR+/HER2- locally advanced or metastatic breast cancer patients. Key upcoming milestones for RLY-2608 program includes presenting data at the San Antonio Breast Cancer Symposium in December 2024 and initiating a phase 3 study in 2025. Expansion o...
More Relay Therapeutics Inc News

Company Profile

Relay Therapeutics, Inc. is a clinical-stage precision medicines company. It focuses on using innovative experimental and computational approaches on protein motion for making medicines against intractable precision medicine targets. The company was founded by David Elliot Shaw, Matthew P. Jacobson, Dorothee Kern, Mark Murcko, Alexis Borisy, and Jakob Loven on May 4, 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Sanjiv Patel
Employees 323
Founded 2015
Website www.relaytx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today